Optiver Holding’s Celldex Therapeutics CLDX Stock Holding History

Optiver Holding’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.3K	Buy	518 +382	+281%	+$12.3K	﹤0.01%	1534
2026 Q1	$4.31K	Buy	136 +16	+13%	+$436	﹤0.01%	1482
2025 Q4	$3.26K	Sell	120 -144	-55%	-$3.79K	﹤0.01%	1702
2025 Q3	$6.83K	Buy	+264	New	+$6.12K	﹤0.01%	1527

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Optiver Holding's CLDX Position: Q2 2026 in Review

Optiver Holding increased its Celldex Therapeutics (CLDX) stake by 281% in Q2 2026, buying an estimated $12.3K and bringing the position to 518 shares worth $19.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1534.

Optiver Holding first reported a position in CLDX in Q3 2025 and has held it in 4 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Optiver Holding held 518 shares of Celldex Therapeutics worth $19.3K as of Q2 2026.
Optiver Holding bought 382 Celldex Therapeutics shares in Q2 2026, an estimated $12.3K.
Celldex Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #1534 holding.
Optiver Holding first reported a position in Celldex Therapeutics in Q3 2025 and has held it in 4 quarters since.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.